Physician profile
Yogesh Govil
NPI 1275514473
$2,211.60
in general payments reported to CMS, 2019-2025
24 companies · $485 in 2025
The $485 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $48.41 · 2021: $206 · 2022: $437 · 2023: $332 · 2024: $545 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,331 · Education: $31.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,330.66 |
| Education | $31.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $600.54 | 2019-2025 | |
| Janssen Biotech, INC. | $304.29 | 2021-2025 | Tremfya, Stelara, Remicade |
| Regeneron Healthcare Solutions, INC. | $167.42 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $165.43 | 2021-2025 | Xifaxan, Relistor, Trulance |
| Genzyme Corporation | $133.94 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.07 | 2020-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $99.71 | 2024-2025 | Ibsrela |
| Pfizer INC. | $99.42 | 2019-2025 | |
| Hologic Sales and Service, LLC | $77.26 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $74.63 | 2021-2023 | Linzess |
| Celgene Corporation | $70.07 | 2021-2023 | Zeposia |
| Boston Scientific Corporation | $46.73 | 2019 | |
| Braintree Laboratories, INC. | $37.89 | 2019-2024 | Suflave |
| Phathom Pharmaceuticals, INC. | $35.33 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $31.38 | 2024 | Zymfentra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $24.66 | 2025 | Zenpep |
| Amgen INC. | $22.24 | 2025 | Uplizna |
| Shire North American Group INC | $18.80 | 2019 | |
| Redhill Biopharma INC. | $18.12 | 2021 | |
| Medtronic, INC. | $18.10 | 2021 | |
| Alfasigma USA, INC. | $14.95 | 2020 | |
| Steris Corporation | $14.93 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.41 | 2021 | |
| Meridian Bioscience INC. | $13.28 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yogesh Govil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.